<DOC>
	<DOCNO>NCT01704495</DOCNO>
	<brief_summary>The purpose Evaluate Efficacy , Safety , Tolerability 3 Different Doses AZD5069 Twice Daily Add-on Treatment Medium High Dose Inhaled Corticosteroids ( ICS ) Long-acting β2 Agonists ( LABA ) , Patients Uncontrolled Persistent Asthma</brief_summary>
	<brief_title>A Phase II Study Evaluate Efficacy , Safety Tolerability AZD5069 Patients With Uncontrolled Persistent Asthma .</brief_title>
	<detailed_description>A 6-month , Randomised , Double-blind , Placebo-controlled , Multi-centre , Parallel-group , Phase II Study Optional Safety Extension Treatment Period 6 month , Evaluate Efficacy , Safety , Tolerability 3 Different Doses AZD5069 Twice Daily Add-on Treatment Medium High Dose Inhaled Corticosteroids ( ICS ) Long-acting β2 Agonists ( LABA ) , Patients Uncontrolled Persistent Asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Men woman age 18 year . Females childbearing potential must use highly effective contraceptive method plus condom male partner . Diagnosis asthma least 12 month ( GINA 2011 ) Uncontrolled persistent asthma , despite treatment medium high dose ICS LABA , history exacerbation last year Morning prebronchodilator FEV1 ≥30 % ≤85 % predict normal enrolment Daily use medium high dose ICS ( ≥fluticasone 500 µg equivalent daily ) Any clinically significant disease disorder ( include chronic low respiratory disease asthma ) may put patient risk influence study result Patients recurrent , latent , chronic infection Active tuberculosis latent tuberculosis without completion appropriate course treatment prophylactic treatment Significant low respiratory tract infection resolve within 30 day prior enrolment Current smoker smoke history 20 pack year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>150 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Uncontrolled Asthma ,</keyword>
	<keyword>Exacerbation ,</keyword>
	<keyword>Safety</keyword>
</DOC>